Clinical trials: Oxaliplatin
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT06124378
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Gastroesophageal Junction Adenocarcinoma
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction
Stage I：preoperative therapy Capecitabine plus oxaliplatin with concurrent radiotherapy is superior to surgery alone ; Stage II: Perioperative therapy Perioperative Capecitabine plus oxaliplatin with Concurrent radiotherapy is…
- Trial name
- A-C (NCT01962246)
- Testing
- Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent radiotherapy
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Hebei Medical University
Stomach Neoplasms
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with recurrent and/or metastastic gastric…
- Trial name
- NCT00515190
- Testing
- S-1,oxaliplatin
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- National Cancer Center, Korea
Metastatic Colorectal Cancer
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
- Trial name
- POLAF (NCT02970916)
- Testing
- FOLFIRI+aflibercept
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Advanced Incurable Solid Malignancy
Study of GemOx and Vandetanib in Advanced Solid Malignancy
This is a research study that will try to find the highest and safest dose of an experimental drug, vandetanib, that can be given in combination with two standard chemotherapy agents, gemcitabine and oxaliplatin, to subjects with…
- Trial name
- NCT00660725
- Testing
- Vandetanib, Gemcitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Leonard Appleman
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
Drugs used in chemotherapy, such as irinotecan, oxaliplatin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074321
- Testing
- irinotecan hydrochloride, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (GemOx) versus standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell…
- Trial name
- NCT07599423
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- China
- Volunteers
- 96 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Rectal Cancer, Locally Advanced
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma
- Trial name
- NCT05868317
- Testing
- Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy
- Where
- Tunisia
- Volunteers
- 70 people
- Sponsor
- Salah Azaïz Cancer Institute
Intrahepatic Cholangiocarcinoma
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated…
- Trial name
- NCT04891289
- Testing
- Gemcitabine, Oxaliplatin, Dexamethasone
- Where
- 11 sites in United States, Netherlands
- Volunteers
- 164 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Colorectal Carcinoma
Phase I FOLFOX Combination
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal…
- Trial name
- NCT00499850
- Testing
- ZD6474 (vandetanib), 5-Fluorouracil, Leucovorin
- Where
- 4 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Stomach Neoplasms
Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
This study is an open-label, single center, and a single arm phase II study to evaluate the clinical response and safety of perioperative S-1 plus docetaxel.
- Trial name
- NCT00587145
- Testing
- S-1,Docetaxel
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- National Cancer Center, Korea
Vitamin D3
XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line…
- Trial name
- NCT03389659
- Testing
- vitamin D3
- Volunteers
- 750 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Gastric cancer with retroperitoneal lymph node metastasis was considered as unresectable, to improve these patients' prognosis, we designed systematic conversion therapy including immunotherapy and chemoradiotherapy.
- Trial name
- NCT05002686
- Testing
- Sintilimab, Albumin-Paclitaxel, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with…
- Trial name
- NCT00165867
- Testing
- E7070
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Eisai Limited
Colorectal Liver Metastases
Folfox-B Study for Patients With Colorectal Liver Metastases
Objective: To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage…
- Trial name
- NCT00508872
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-induced Peripheral Neuropathy
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
To evaluate the efficacy and safety of ART-123 on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy
- Trial name
- NCT04492436
- Testing
- thrombomodulin alfa
- Sponsor
- Veloxis Pharmaceuticals
S-1 Plus Oxaliplatin
Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer
Elderly patients have poor tolerance and physical condition, we will prove 2-week schedule of oxaliplatin plus S-1 have a good efficacy and a better safety for elderly patients with advanced or recurrent gastric cancer.
- Trial name
- NCT04694404
- Testing
- S-1,Oxaliplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Aiping Zhou
Peritoneal Cavity Cancer
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625092
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer Metastatic
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3…
- Trial name
- VISNU-2 (NCT01640444)
- Testing
- FOLFIRI + bevacizumab, FOLFIRI + cetuximab
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)